J. Goldman & Co LP purchased a new stake in Alumis Inc. (NASDAQ:ALMS – Free Report) during the 2nd quarter, Holdings Channel reports. The fund purchased 25,846 shares of the company’s stock, valued at approximately $727,000.
A number of other hedge funds have also modified their holdings of the business. California State Teachers Retirement System lifted its holdings in Alumis by 2,222.5% in the 1st quarter. California State Teachers Retirement System now owns 80,845 shares of the company’s stock valued at $1,781,000 after purchasing an additional 77,364 shares in the last quarter. First Trust Advisors LP acquired a new position in shares of Alumis in the first quarter valued at approximately $1,456,000. The Manufacturers Life Insurance Company lifted its stake in shares of Alumis by 775.6% during the first quarter. The Manufacturers Life Insurance Company now owns 154,634 shares of the company’s stock valued at $3,407,000 after buying an additional 136,973 shares during the period. Swiss National Bank acquired a new stake in Alumis during the first quarter worth approximately $2,815,000. Finally, Elmind Capital LP purchased a new stake in Alumis in the 1st quarter worth approximately $2,864,000.
Alumis Trading Down 1.4%
ALMS stock opened at $23.62 on Thursday. The stock has a 50-day moving average price of $26.58 and a two-hundred day moving average price of $25.13. Alumis Inc. has a 12-month low of $3.76 and a 12-month high of $31.35. The company has a market cap of $3.06 billion, a PE ratio of -6.12 and a beta of -0.69.
Insider Activity
In other Alumis news, insider Roy C. Hardiman sold 2,692 shares of Alumis stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $70,988.04. Following the transaction, the insider directly owned 207,746 shares of the company’s stock, valued at $5,478,262.02. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider David M. Goldstein sold 2,596 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $68,456.52. Following the sale, the insider owned 30,970 shares of the company’s stock, valued at approximately $816,678.90. This represents a 7.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 19,953 shares of company stock worth $534,311. Insiders own 33.70% of the company’s stock.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the company. Chardan Capital increased their price target on Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, May 19th. Citigroup reaffirmed a “neutral” rating on shares of Alumis in a research report on Monday, August 17th. Wall Street Zen upgraded Alumis from a “strong sell” rating to a “hold” rating in a research note on Sunday. Guggenheim increased their target price on Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Alumis currently has a consensus rating of “Moderate Buy” and an average target price of $40.30.
View Our Latest Stock Report on Alumis
Alumis Company Profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
See Also
- Five stocks we like better than Alumis
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding ALMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alumis Inc. (NASDAQ:ALMS – Free Report).
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
